The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus

Background: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date on which the v...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M.D. Maldonado, J. Romero-Aibar
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	The anti-SARS-CoV-2 vaccines mRNA-based vaccines Herpes zoster infection Immune system Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/23be77dddc9e42f0b6e57073acd6fead
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:23be77dddc9e42f0b6e57073acd6fead
record_format	dspace
spelling	oai:doaj.org-article:23be77dddc9e42f0b6e57073acd6fead2021-11-04T04:40:07ZThe Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus2666-354610.1016/j.bbih.2021.100381https://doaj.org/article/23be77dddc9e42f0b6e57073acd6fead2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666354621001848https://doaj.org/toc/2666-3546Background: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date on which the vaccination program began in Spain and across Europe. The aim of this study is to monitor the safety of anti-SARS-CoV-2 vaccines and report any cases of undesirable effects that have occurred, that are not included in the health profile of mRNA-based vaccines for commercialisation in humans. Furthermore, a brief review is given of the mechanism of action of the anti-SARS-CoV-2 vaccine on the host's immune system in triggering the reactivation of the herpes varicella-zoster infection. Methods: Follow-up of patients under the care of the southern health district of Seville of the SAS (Andalusian Health Service) during the Spanish state of alarm over the COVID-19 pandemic. Results: Two patients, a 79-year-old man and a 56-year-old woman, are reported who, after 4 and 16 days respectively of receiving the Pfizer-BNT162b2 vaccine against SARS-CoV-2, presented a state of reactivation of herpes varicella-zoster virus (VZV). Discussion: The immunosenescence of the reported patients, together with the immunomodulation generated by administering the anti-SARS-CoV-2 vaccines, that depress certain cell subpopulations, could explain the awakening of VZV latency.M.D. MaldonadoJ. Romero-AibarElsevierarticleThe anti-SARS-CoV-2 vaccinesmRNA-based vaccinesHerpes zoster infectionImmune systemNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain, Behavior, & Immunity - Health, Vol 18, Iss , Pp 100381- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	The anti-SARS-CoV-2 vaccines mRNA-based vaccines Herpes zoster infection Immune system Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	The anti-SARS-CoV-2 vaccines mRNA-based vaccines Herpes zoster infection Immune system Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 M.D. Maldonado J. Romero-Aibar The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
description	Background: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date on which the vaccination program began in Spain and across Europe. The aim of this study is to monitor the safety of anti-SARS-CoV-2 vaccines and report any cases of undesirable effects that have occurred, that are not included in the health profile of mRNA-based vaccines for commercialisation in humans. Furthermore, a brief review is given of the mechanism of action of the anti-SARS-CoV-2 vaccine on the host's immune system in triggering the reactivation of the herpes varicella-zoster infection. Methods: Follow-up of patients under the care of the southern health district of Seville of the SAS (Andalusian Health Service) during the Spanish state of alarm over the COVID-19 pandemic. Results: Two patients, a 79-year-old man and a 56-year-old woman, are reported who, after 4 and 16 days respectively of receiving the Pfizer-BNT162b2 vaccine against SARS-CoV-2, presented a state of reactivation of herpes varicella-zoster virus (VZV). Discussion: The immunosenescence of the reported patients, together with the immunomodulation generated by administering the anti-SARS-CoV-2 vaccines, that depress certain cell subpopulations, could explain the awakening of VZV latency.
format	article
author	M.D. Maldonado J. Romero-Aibar
author_facet	M.D. Maldonado J. Romero-Aibar
author_sort	M.D. Maldonado
title	The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
title_short	The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
title_full	The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
title_fullStr	The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
title_full_unstemmed	The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
title_sort	pfizer-bnt162b2 mrna-based vaccine against sars-cov-2 may be responsible for awakening the latency of herpes varicella-zoster virus
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/23be77dddc9e42f0b6e57073acd6fead
work_keys_str_mv	AT mdmaldonado thepfizerbnt162b2mrnabasedvaccineagainstsarscov2mayberesponsibleforawakeningthelatencyofherpesvaricellazostervirus AT jromeroaibar thepfizerbnt162b2mrnabasedvaccineagainstsarscov2mayberesponsibleforawakeningthelatencyofherpesvaricellazostervirus AT mdmaldonado pfizerbnt162b2mrnabasedvaccineagainstsarscov2mayberesponsibleforawakeningthelatencyofherpesvaricellazostervirus AT jromeroaibar pfizerbnt162b2mrnabasedvaccineagainstsarscov2mayberesponsibleforawakeningthelatencyofherpesvaricellazostervirus
_version_	1718445196953255936

The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus

Ejemplares similares